« Back to Record
Citation APA

Rohrberg, K., Brandão, M., Castanon Alvarez, E., Felip, E., Gort, E., Hiltermann, J. N., Izumi, H., Kim, D.-W., Kim, S. W., Paz Ares, L., Solomon, B., Steinbusch, L., Wauters, E., Yoshida, T., Chen, H., Goldwin, A., Jiang, Y., Achour, I., Drachsler, M. W., & Cho, B. C. (2023). Safety, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of AZD2936, a bispecific antibody targeting PD-1 and TIGIT, in checkpoint inhibitor (CPI)-experienced advanced/metastatic non-small-cell lung cancer (NSCLC): First report of ARTEMIDE-01. Journal of clinical oncology, 41(16_suppl), 9050-9050. doi:10.1200/JCO.2023.41.16_suppl.9050


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/401717

Rohrberg, K., Brandão, M., Castanon Alvarez, E., Felip, E., Gort, E., Hiltermann, J. N., Izumi, H., Kim, D.-W., Kim, S. W., Paz Ares, L., Solomon, B., Steinbusch, L., Wauters, E., Yoshida, T., Chen, H., Goldwin, A., Jiang, Y., Achour, I., Drachsler, M. W., & Cho, B. C. (2023). Safety, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of AZD2936, a bispecific antibody targeting PD-1 and TIGIT, in checkpoint inhibitor (CPI)-experienced advanced/metastatic non-small-cell lung cancer (NSCLC): First report of ARTEMIDE-01. Journal of clinical oncology, 41(16_suppl), 9050-9050. doi:10.1200/JCO.2023.41.16_suppl.9050